Table 1.
Baseline characteristics of trial population.
| SZ-A (n = 23) | Acarbose (n = 15) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 56 (9.71) | 57 (6.70) | 0.747a |
| Gender (male/female) | 8/15 | 5/10 | 1.000b |
|
| |||
| Comorbidities | |||
| Hypertension | 6 (26.1%) | 6 (40.0%) | 0.481b |
| Hyperlipidaemia | 17 (73.9%) | 10 (66.7%) | 0.722b |
|
| |||
| Concomitant drug use | |||
| Metformin | 12 (52%) | 7 (47%) | 1.000b |
| Antilipidemic | 2 (0.09%) | 0 | NA |
| Antihypertensive | 1 (0.04%) | 0 | NA |
|
| |||
| Metabolic factors | |||
| Disease duration (months) | 36 (6,180) | 30 (9,120) | 0.800c |
| Fasting glucose (mmol/L) | 8.94 (1.63) | 8.85 (1.56) | 0.873a |
| HbA1c (%) | 8.30 (0.91) | 8.24 (0.95) | 0.847a |
| Weight (kg) | 71.63 (12.06) | 69.30 (13.00) | 0.576a |
| BMI (kg/m2) | 25.67 (2.744) | 25.47 (2.612) | 0.822a |
| Systolic blood pressure (mmHg) | 131.48 (11.735) | 129.67 (15.267) | 0.682a |
| Diastolic blood pressure (mmHg) | 81.39 (8.217) | 78.67 (9.123) | 0.345a |
| Smoking history (current smoker) | 1 (4.3%) | 4 (26.7%) | 0.069b |
| Drinking history (current drinker) | 2 (8.7%) | 0 | NA |
| Proteinuria | 0.898c | ||
| 0 | 12 (63.2%) | 9 (64.3%) | — |
| Trace | 5 (26.3%) | 4 (28.6%) | — |
| 1+ | 2 (10.5%) | 1 (7.1%) | — |
| Glycosuria | |||
| 0 | 12 (63.2%) | 7 (50.0%) | 1.000b |
| Trace | 2 (10.5%) | 3 (21.4%) | 0.365d |
| 1+ | 0 | 1 (7.1%) | NA |
| 2+ | 0 | 0 | NA |
| 3+ | 2 (10.5%) | 3 (21.4%) | 0.365d |
| 4+ | 3 (15.8%) | 0 | NA |
|
| |||
| Lipids | |||
| Total cholesterol (mmol/L) | 5.17 (1.06) | 4.85 (0.91) | 0.350a |
| Triglycerides (mmol/L) | 2.26 (1.30) | 1.89 (1.12) | 0.367a |
| HDL (mmol/L) | 1.18 (0.37) | 1.15 (0.27) | 0.803a |
| LDL (mmol/L) | 3.04 (0.93) | 2.97 (0.69) | 0.790a |
|
| |||
| Liver function tests | |||
| Alanine aminotransferase (U/L) | 22.39 (9.41) | 26.60 (15.04) | 0.294a |
| Aspartate aminotransferase (U/L) | 17.91 (5.43) | 20.07 (6.27) | 0.269a |
|
| |||
| Kidney function tests | |||
| Creatinine clearance (mL/min) | 77.08 (20.66) | 76.59 (14.56) | 0.937a |
| Uric acid (mmol/L) | 292.91 (80.62) | 241.20 (90.95) | 0.078a |
|
| |||
| ECG | |||
| Normal | 11 (57.89%) | 7 (50%) | 1.000b |
| ST segment depression | 2 (10.53%) | 0 (0%) | NA |
| T wave nonspecific changes | 3 (15.79%) | 3 (21.43%) | 0.663d |
| Low voltage | 1 (5.26%) | 0 (0%) | NA |
| High voltage of left ventricle | 1 (5.26%) | 1 (7.14%) | 1.000d |
| PR interval shortened | 1 (5.26%) | 0 (0%) | NA |
| Left ventricle hypertrophy | 0 (0%) | 1 (7.14%) | NA |
| Right atrium hypertrophy | 0 (0%) | 1 (7.14%) | NA |
| Sinus bradycardia | 0 (0%) | 1 (7.14%) | NA |
|
| |||
| Compliance (%) | 97.66 (2.95) | 97.36 (2.08) | 0.734a |
Data are mean (SD) or n (%) or median (minimum, maximum). aIndependent-samples t-test. bChi-square tests (Fisher's exact test). cNonparametric tests. dChi-square tests (Monte Carlo exact test).